ioforminol
Small moleculeexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2009 (NCT01004770)
Timeline
Indications
Mechanism of action
- Unspecified targetOTHER
Diagnostic
- Unspecified targetContrast agent
contrast agent
Chemistry & pharmacology
Loading structure…
SMILES
O=CN(CC(O)CN(C=O)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I- Mol. weight
- 1522.13 g/mol
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2219417 ↗
Also known as
- 5-(formyl-(3-(formyl-(3,5-bis (2,3-dihydroxypropylcarbamoyl)-2,4,6-triiodophenyl) amino)-2-hydroxypropyl)amino)-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
- fek-256-062
- fek-256-062
- ge 145
- ge-145
- ge-145
- ge-145
- ge145 cpd
- ioforminol
- ioforminol
- ioforminol
- ioforminol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01672996 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2012 | General Electric, IQVIA |
| NCT01252810 | Phase 2 | Nov 1, 2010 | General Electric, Medpace, Inc., Optum, Rules-Based Medicine, Inc. |
| NCT01004770 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2009 | General Electric, Medpace, Inc., Optum |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| General Electric | For profit | 3 | 3 | 1 | 2009 |
| Medpace, Inc. | For profit | 2 | 0 | 1 | 2009 |
| Optum | For profit | 2 | 0 | 1 | 2009 |
| IQVIA | For profit | 1 | 0 | 1 | 2012 |
| Rules-Based Medicine, Inc. | For profit | 1 | 0 | 1 | 2010 |
5 organizations
Page 1 / 1